Contents
23 January 2019
Vol 11, Issue 476
Vol 11, Issue 476
Perspective
- Rapamycin and Alzheimer’s disease: Time for a clinical trial?
In this Perspective, the authors propose that clinical testing of rapamycin in patients with Alzheimer’s disease is long overdue.
Research Articles
- Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
An oncolytic adenovirus shows antitumor efficacy in patient-derived models of intraocular retinoblastoma and appears safe for human use.
- Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin
Mutations in MYBPC3 disrupt myosin states of relaxation, and manipulating myosin therapeutically abates the effects of MYBPC3 mutations.
- Cyclin G1 and TASCC regulate kidney epithelial cell G2-M arrest and fibrotic maladaptive repair
Cyclin G1 regulates G2-M arrest in proximal tubular cells, promoting a TASCC-induced secretory phenotype, fibrosis, and kidney disease progression.
- A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer
HER2 remains a therapeutic target in drug-resistant HER2-positive breast cancer, and a recombinant human protein overcomes the drug resistance.
Editors' Choice
- Brain development in autism: Timing is everything
Gene network analysis in stem cell–derived cortical neurons from individuals with autism reveals accelerated neuronal maturation.
- Disappearing pressure cuffs
Wireless, biodegradable pressure sensors provide continuous short-term monitoring of arterial pulse in rats.
- IL-6: A hack to body fat and exercise?
The IL-6 receptor antibody tocilizumab abolished the ability of exercise to reduce visceral fat and cholesterol levels in obese individuals.
Erratum
About The Cover
ONLINE COVER Blasting Retinoblastoma. The image shows human retinoblastoma cells (dark purple) on top of retinal layers, which are stained to show the RB1 protein (brown). An oncolytic virus that targets cells with a defective RB1 pathway, such as these retinoblastoma cells, was tested in animal models of this tumor (Pascual-Pasto et al.). The virus was safe in juvenile rabbits and improved survival in mouse models of retinoblastoma. Intravitreous administration of the virus was safe in the first two patients enrolled in a clinical trial, with signs of antitumor activity observed. These promising results could lead to the development of an oncolytic virus therapy that spares many children from surgical eye removal. [CREDIT: ANGEL MONTERO CARCABOSO/INSTITUT DE RECERCA SANT JOAN DE DEU]
